O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 20 Trials 
33 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodriguez, Maria A
INTENSE, NCT05394298: Short vs Long of Usual Treatment for Non Complicated Enterococcal Bacteremia

Recruiting
4
284
Europe
Short-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia., 7 days of active antibiotics, Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia., 14 days of active antibiotics
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Spanish Network for Research in Infectious Diseases, Spanish Clinical Research Network - SCReN
Enterococcal Bacteremia
07/24
12/24
PTOS, NCT06768320: Treating Toddler Obesity by Treating the Parent/Caregiver Obesity with Weight Loss Medications

Not yet recruiting
4
50
US
Lomaira 8Mg Tablet
Loma Linda University
Weight Loss, Obesity, Childhood, Obesity
01/26
11/27
ASUCOV, NCT05639192: Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

Terminated
3
34
Europe, RoW
Asunercept, Placebo
Apogenix GmbH
COVID-19
08/23
08/23
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
243
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
NCT06374394: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Active, not recruiting
3
842
Europe, US
RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
11/24
05/25
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Ianalumab (VAY736), VAY736, Placebo
Novartis Pharmaceuticals
Sjogrens Syndrome
08/28
07/30
VALLMDMA_001, NCT04264026: MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD

Active, not recruiting
2
5
US
3,4-methylenedioxymethamphetamine, MDMA
VA Loma Linda Health Care System, Multidisciplinary Association for Psychedelic Studies
Post Traumatic Stress Disorder, Combat Stress Disorders
12/24
04/25
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Recruiting
2
118
Europe, Canada, US, RoW
Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA
Karyopharm Therapeutics Inc
Myelofibrosis, Moderate Thrombocytopenia
04/26
10/28
NCT05020860: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Recruiting
2
185
US
Paclitaxel, Taxol, Carboplatin, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Pembrolizumab, Keytruda, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, PHESGO
Baylor Breast Care Center
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
08/27
11/29
LINKER-MM1, NCT03761108 / 2018-003188-78: Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

Checkmark Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Checkmark Completion of enrollment of trial for r/r multiple myeloma
Dec 2022 - Dec 2022: Completion of enrollment of trial for r/r multiple myeloma
Checkmark Data from P1 portion of P1/2 trial for multiple myeloma at ASH 2021
More
Recruiting
1/2
387
Europe, Japan, US, RoW
Linvoseltamab, REGN5458
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Multiple Myeloma
05/32
06/32
Noelia, NCT05265650: Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

Recruiting
1/2
30
Europe
BO-112 in combination with ablative radiotherapy (SABR) and nivolumab, BO-112 with radiotherapy and nivolumab, Tissue Biopsies
Clinica Universidad de Navarra, Universidad de Navarra, Highlight Therapeutics
Non-Small Cell Lung Cancer Metastatic
03/24
06/24
PEARL, NCT03830567: Pharmacists Expand Access to Reproductive heaLthcare

Completed
N/A
471
US
Pharmacist prescription, Clinician prescription
Oregon Health and Science University, Laura and John Arnold Foundation
Contraception
02/21
02/22
ESTAMPA, NCT01881659: Cervical Cancer Screening With Human Papillomavirus Testing

Active, not recruiting
N/A
50000
RoW
HPV screening
International Agency for Research on Cancer
CIN3, CIN2, Cervical Cancer
08/22
12/23
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
NCT03478553: The Genetics of Pulmonary Fibrosis

Recruiting
N/A
1000
US
Blood draw, Questionnaire
University of Colorado, Denver, United States Department of Defense, University of Alabama at Birmingham, National Jewish Health, University of California, San Francisco, University of Pittsburgh, Baylor University
Idiopathic Pulmonary Fibrosis (IPF)
12/26
12/26
SBA, NCT06309264: Comparing Hearing Aid Fitting Methods in Blast-exposed Veterans

Recruiting
N/A
80
US
Phonak Lumina P90
VA Office of Research and Development, University of California, San Diego, NADI Inc.
Auditory Diseases, Central
03/28
03/28
NCT06833567: Mentalizing and Epistemic Trust in Patients with Anxiety and Depression.

Recruiting
N/A
100
Europe
Brief mentalization-based group psychotherapy, Acceptance and Commitment Therapy group intervention
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Anxiety Disorders, Depression
05/26
06/26
OSPREY, NCT04493632: is a Post-market, Global, Multicentre, Observational, Prospective Registry.

Recruiting
N/A
500
Europe
OncoSil Medical Limited
Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasm, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases
11/25
10/27
PMH-RW, NCT05654987: Perinatal Mental Health for Refugee Women

Recruiting
N/A
600
Europe, RoW
Universidad Nacional de Educación a Distancia, University of Gdansk, Taras Shevchenko National University of Kyiv
Perinatal Depression
07/23
10/23
Rimawi, Mothaffar
NCT02003209: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Active, not recruiting
3
315
US
Aromatase Inhibition Therapy, Aromatase Inhibition, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cytology Specimen Collection Procedure, Cytologic Sampling, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, Quality-of-Life Assessment, Quality of Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Whole Breast Irradiation
National Cancer Institute (NCI), NRG Oncology
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
10/16
12/25
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
HELEX, NCT00999804: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Active, not recruiting
2
128
US
Lapatinib, TyKerb, Letrozole, Femara, Trastuzumab, Herceptin
Baylor Breast Care Center, Translational Breast Cancer Research Consortium, GlaxoSmithKline
Breast Cancer
11/14
01/26
TACTIC, NCT03093350: - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

Active, not recruiting
2
12
US
TAA-specific CTLs
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine, National Cancer Institute (NCI), Cancer Prevention Research Institute of Texas
Breast Cancer
05/19
05/25
CADENCE, NCT02547987: Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer

Active, not recruiting
2
25
US
Docetaxel, Taxotere, Carboplatin, Paraplatin
Mothaffar Rimawi
Breast Cancer
06/19
09/25
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
09/24
07/27
TBCRC 042, NCT02928978: Ruxolitinib for Premalignant Breast Disease

Active, not recruiting
2
100
US
Ruxolitinib, Jakafi, INCB018424, Placebo (for Ruxolitinib)
Julie Nangia, Incyte Corporation, Translational Breast Cancer Research Consortium
Ductal Carcinoma in Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
01/26
06/26
NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Recruiting
2
2156
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
NCT05020860: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Recruiting
2
185
US
Paclitaxel, Taxol, Carboplatin, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Pembrolizumab, Keytruda, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, PHESGO
Baylor Breast Care Center
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
08/27
11/29
SIMPHONY, NCT03324425: Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

Active, not recruiting
2
5
US
Simvastatin 80mg, Zocor
Baylor Breast Care Center
Breast Cancer Stage IV
12/28
12/30
NCT03950570: ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Completed
1/2
58
US
Abraxane, ORIN1001
Orinove, Inc.
Advanced Solid Tumor, Metastatic Breast Cancer
01/23
01/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodriguez, Maria A
INTENSE, NCT05394298: Short vs Long of Usual Treatment for Non Complicated Enterococcal Bacteremia

Recruiting
4
284
Europe
Short-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia., 7 days of active antibiotics, Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia., 14 days of active antibiotics
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Spanish Network for Research in Infectious Diseases, Spanish Clinical Research Network - SCReN
Enterococcal Bacteremia
07/24
12/24
PTOS, NCT06768320: Treating Toddler Obesity by Treating the Parent/Caregiver Obesity with Weight Loss Medications

Not yet recruiting
4
50
US
Lomaira 8Mg Tablet
Loma Linda University
Weight Loss, Obesity, Childhood, Obesity
01/26
11/27
ASUCOV, NCT05639192: Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

Terminated
3
34
Europe, RoW
Asunercept, Placebo
Apogenix GmbH
COVID-19
08/23
08/23
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
243
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
NCT06374394: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Active, not recruiting
3
842
Europe, US
RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
11/24
05/25
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Ianalumab (VAY736), VAY736, Placebo
Novartis Pharmaceuticals
Sjogrens Syndrome
08/28
07/30
VALLMDMA_001, NCT04264026: MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD

Active, not recruiting
2
5
US
3,4-methylenedioxymethamphetamine, MDMA
VA Loma Linda Health Care System, Multidisciplinary Association for Psychedelic Studies
Post Traumatic Stress Disorder, Combat Stress Disorders
12/24
04/25
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Recruiting
2
118
Europe, Canada, US, RoW
Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA
Karyopharm Therapeutics Inc
Myelofibrosis, Moderate Thrombocytopenia
04/26
10/28
NCT05020860: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Recruiting
2
185
US
Paclitaxel, Taxol, Carboplatin, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Pembrolizumab, Keytruda, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, PHESGO
Baylor Breast Care Center
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
08/27
11/29
LINKER-MM1, NCT03761108 / 2018-003188-78: Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

Checkmark Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Checkmark Completion of enrollment of trial for r/r multiple myeloma
Dec 2022 - Dec 2022: Completion of enrollment of trial for r/r multiple myeloma
Checkmark Data from P1 portion of P1/2 trial for multiple myeloma at ASH 2021
More
Recruiting
1/2
387
Europe, Japan, US, RoW
Linvoseltamab, REGN5458
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Multiple Myeloma
05/32
06/32
Noelia, NCT05265650: Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

Recruiting
1/2
30
Europe
BO-112 in combination with ablative radiotherapy (SABR) and nivolumab, BO-112 with radiotherapy and nivolumab, Tissue Biopsies
Clinica Universidad de Navarra, Universidad de Navarra, Highlight Therapeutics
Non-Small Cell Lung Cancer Metastatic
03/24
06/24
PEARL, NCT03830567: Pharmacists Expand Access to Reproductive heaLthcare

Completed
N/A
471
US
Pharmacist prescription, Clinician prescription
Oregon Health and Science University, Laura and John Arnold Foundation
Contraception
02/21
02/22
ESTAMPA, NCT01881659: Cervical Cancer Screening With Human Papillomavirus Testing

Active, not recruiting
N/A
50000
RoW
HPV screening
International Agency for Research on Cancer
CIN3, CIN2, Cervical Cancer
08/22
12/23
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
NCT03478553: The Genetics of Pulmonary Fibrosis

Recruiting
N/A
1000
US
Blood draw, Questionnaire
University of Colorado, Denver, United States Department of Defense, University of Alabama at Birmingham, National Jewish Health, University of California, San Francisco, University of Pittsburgh, Baylor University
Idiopathic Pulmonary Fibrosis (IPF)
12/26
12/26
SBA, NCT06309264: Comparing Hearing Aid Fitting Methods in Blast-exposed Veterans

Recruiting
N/A
80
US
Phonak Lumina P90
VA Office of Research and Development, University of California, San Diego, NADI Inc.
Auditory Diseases, Central
03/28
03/28
NCT06833567: Mentalizing and Epistemic Trust in Patients with Anxiety and Depression.

Recruiting
N/A
100
Europe
Brief mentalization-based group psychotherapy, Acceptance and Commitment Therapy group intervention
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Anxiety Disorders, Depression
05/26
06/26
OSPREY, NCT04493632: is a Post-market, Global, Multicentre, Observational, Prospective Registry.

Recruiting
N/A
500
Europe
OncoSil Medical Limited
Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasm, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases
11/25
10/27
PMH-RW, NCT05654987: Perinatal Mental Health for Refugee Women

Recruiting
N/A
600
Europe, RoW
Universidad Nacional de Educación a Distancia, University of Gdansk, Taras Shevchenko National University of Kyiv
Perinatal Depression
07/23
10/23
Rimawi, Mothaffar
NCT02003209: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Active, not recruiting
3
315
US
Aromatase Inhibition Therapy, Aromatase Inhibition, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cytology Specimen Collection Procedure, Cytologic Sampling, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, Quality-of-Life Assessment, Quality of Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Whole Breast Irradiation
National Cancer Institute (NCI), NRG Oncology
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
10/16
12/25
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
HELEX, NCT00999804: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Active, not recruiting
2
128
US
Lapatinib, TyKerb, Letrozole, Femara, Trastuzumab, Herceptin
Baylor Breast Care Center, Translational Breast Cancer Research Consortium, GlaxoSmithKline
Breast Cancer
11/14
01/26
TACTIC, NCT03093350: - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

Active, not recruiting
2
12
US
TAA-specific CTLs
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine, National Cancer Institute (NCI), Cancer Prevention Research Institute of Texas
Breast Cancer
05/19
05/25
CADENCE, NCT02547987: Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer

Active, not recruiting
2
25
US
Docetaxel, Taxotere, Carboplatin, Paraplatin
Mothaffar Rimawi
Breast Cancer
06/19
09/25
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
09/24
07/27
TBCRC 042, NCT02928978: Ruxolitinib for Premalignant Breast Disease

Active, not recruiting
2
100
US
Ruxolitinib, Jakafi, INCB018424, Placebo (for Ruxolitinib)
Julie Nangia, Incyte Corporation, Translational Breast Cancer Research Consortium
Ductal Carcinoma in Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
01/26
06/26
NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Recruiting
2
2156
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
NCT05020860: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Recruiting
2
185
US
Paclitaxel, Taxol, Carboplatin, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Pembrolizumab, Keytruda, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, PHESGO
Baylor Breast Care Center
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
08/27
11/29
SIMPHONY, NCT03324425: Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

Active, not recruiting
2
5
US
Simvastatin 80mg, Zocor
Baylor Breast Care Center
Breast Cancer Stage IV
12/28
12/30
NCT03950570: ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Completed
1/2
58
US
Abraxane, ORIN1001
Orinove, Inc.
Advanced Solid Tumor, Metastatic Breast Cancer
01/23
01/23

Download Options